The Madras High Court on Thursday ordered the Center to explain by Friday the reason for its partnership with Dr Reddy’s laboratory in Hyderabad only for such production.
A division bench comprising Judge N Kirubakaran and TV Thamilselvi before whom a plea in this regard was presented asked the Center to explain why the DRDO had not licensed as many reputable laboratories as possible to increase production. oral powder which has been approved for use as an adjuvant in the treatment of moderate to severe COVID-19 patients. “It was imperative on the part of the government to give production a boost, especially when lakhs died in the first two waves of the pandemic and the threat of the third wave loomed,” said the Judge Kirubakaran.
Public interest litigation filed in this regard by Dr Saravanan, a private sector employee in Chennai, argued that the Institute of Nuclear Medicine and Allied Sciences (INMAS) of DRDO developed Oral Powder 2- DG and obtained an emergency use authorization from the medication controller. General of India. But the license to manufacture the drug had only been granted to Dr Reddy’s laboratory in Hyderabad, his lawyer said. The advocacy further pointed out that if the said laboratory had planned to sell it at Rs 990 per sachet containing 2.34g of oral powder, such a monopoly would not bode well in these difficult times when thousands of lives were being lost to cause of the pandemic. On this basis, the advocacy aimed at granting such a license to several pharmaceutical companies and also ordered the DRDO to not only share the technical know-how about the medicine with several pharmaceutical companies, but also to ensure that it was sold at an affordable price.